Low Risk of OHSS with Follitropin Delta Use in Women with Different Polycystic Ovary Syndrome Phenotypes: a Retrospective Case Series

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2021 Feb 13

PMID 33579321

Citations 6

Authors

Stephanie Yacoub

Kenneth Cadesky

Robert F Casper

Affiliations

Soon will be listed here.

Abstract

Background: To explore the efficacy of follitropin delta in ovarian stimulation of patients with the Rotterdam ESHRE/ASRM 2003 phenotypes of polycystic ovarian syndrome (PCOS) using a retrospective case series with an electronic file search in a reproductive medicine clinic.

Case Presentation: Seventy-four patients with PCOS undergoing ovarian stimulation according to the individualized dosing algorithm of follitropin delta for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI)/oocyte freezing were included. Follitropin delta resulted in a high number of pre-ovulatory follicles at the end of stimulation as expected in patients with PCOS. There was a large number of oocytes retrieved with an acceptable percentage of metaphase II (MII) oocytes. There were no cases of moderate or severe OHSS across all phenotypes.

Conclusion: Follitropin delta, using the individualized dosing algorithm, appears to be a safe method of ovarian stimulation with a low risk of OHSS in PCOS patients without sacrificing successful stimulation outcomes.

Citing Articles

Ovarian Hyperstimulation Syndrome (OHSS): A Narrative Review and Legal Implications.

Gullo G, Cucinella G, Stojanovic V, Stojkovic M, Bruno C, Streva A J Pers Med. 2024; 14(9).

PMID: 39338169 PMC: 11433561. DOI: 10.3390/jpm14090915.

The pregnancy outcomes among women receiving individualized algorithm dosing with follitropin delta: a systematic review of randomized controlled trials.

Doroftei B, Ilie O, Dabuleanu A, Armeanu T, Maftei R J Assist Reprod Genet. 2024; 41(7):1851-1861.

PMID: 38809330 PMC: 11263530. DOI: 10.1007/s10815-024-03146-1.

Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis.

Palomba S, Caserta D, Levi-Setti P, Busnelli A J Ovarian Res. 2024; 17(1):60.

PMID: 38486276 PMC: 10938807. DOI: 10.1186/s13048-024-01372-w.

Algorithm vs. clinical experience: controlled ovarian stimulations with follitropin-delta and individualised doses of follitropin-alpha/beta.

Gazzo I, Bovis F, Colia D, Sozzi F, Costa M, Anserini P Reprod Fertil. 2024; .

PMID: 38330591 PMC: 10959055. DOI: 10.1530/RAF-23-0045.

Inadvertent Administration of 72 µg of Follitropin-Δ for Three Consecutive Days Does Not Appear to Be Dangerous for Poor Responders: A Case Series.

Baldini G, Mastrorocco A, Sciorio R, Palini S, Dellino M, Cascardi E J Clin Med. 2023; 12(16).

PMID: 37629245 PMC: 10456029. DOI: 10.3390/jcm12165202.

References

Goverde A, van Koert A, Eijkemans M, Knauff E, Westerveld H, Fauser B . Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod. 2008; 24(3):710-7. DOI: 10.1093/humrep/den433. View

Briggs R, Kovacs G, MacLachlan V, Motteram C, Baker H . Can you ever collect too many oocytes?. Hum Reprod. 2014; 30(1):81-7. DOI: 10.1093/humrep/deu272. View

Drakopoulos P, Blockeel C, Stoop D, Camus M, De Vos M, Tournaye H . Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?. Hum Reprod. 2016; 31(2):370-6. DOI: 10.1093/humrep/dev316. View

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.004. View

Al-Inany H, Youssef M, Ayeleke R, Brown J, Lam W, Broekmans F . Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016; 4:CD001750. PMC: 8626739. DOI: 10.1002/14651858.CD001750.pub4. View

Tal R, Seifer D, Khanimov M, Malter H, Grazi R, Leader B . Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol. 2014; 211(1):59.e1-8. DOI: 10.1016/j.ajog.2014.02.026. View

Kumar P, Farouk Sait S, Sharma A, Kumar M . Ovarian hyperstimulation syndrome. J Hum Reprod Sci. 2011; 4(2):70-5. PMC: 3205536. DOI: 10.4103/0974-1208.86080. View

Papanikolaou E, Pozzobon C, Kolibianakis E, Camus M, Tournaye H, Fatemi H . Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006; 85(1):112-20. DOI: 10.1016/j.fertnstert.2005.07.1292. View

Fischer D, Reisenbuchler C, Rosner S, Haussmann J, Wimberger P, Goeckenjan M . Avoiding OHSS: Controlled Ovarian Low-Dose Stimulation in Women with PCOS. Geburtshilfe Frauenheilkd. 2016; 76(6):718-726. PMC: 4922889. DOI: 10.1055/s-0042-100206. View

10.

Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R . Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016; 106(1):6-15. DOI: 10.1016/j.fertnstert.2016.05.003. View

11.

Nyboe Andersen A, Nelson S, Fauser B, Garcia-Velasco J, Klein B, Arce J . Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2016; 107(2):387-396.e4. DOI: 10.1016/j.fertnstert.2016.10.033. View

12.

Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D . Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 2008; 296(2):E238-43. DOI: 10.1152/ajpendo.90684.2008. View

13.

Fernandez-Sanchez M, Visnova H, Yuzpe A, Klein B, Mannaerts B, Arce J . Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles. Reprod Biomed Online. 2019; 38(4):528-537. DOI: 10.1016/j.rbmo.2018.12.032. View

14.

Ovarian Stimulation T, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P . ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open. 2020; 2020(2):hoaa009. PMC: 7203749. DOI: 10.1093/hropen/hoaa009. View

15.

Humaidan P, Quartarolo J, Papanikolaou E . Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010; 94(2):389-400. DOI: 10.1016/j.fertnstert.2010.03.028. View

16.

Selcuk S, Ozkaya E, Eser A, Kuyucu M, Kutlu H, Devranoglu B . Characteristics and outcomes of in vitro fertilization in different phenotypes of polycystic ovary syndrome. Turk J Obstet Gynecol. 2017; 13(1):1-6. PMC: 5558348. DOI: 10.4274/tjod.90094. View

17.

Bosch E, Havelock J, Martin F, Rasmussen B, Klein B, Mannaerts B . Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online. 2018; 38(2):195-205. DOI: 10.1016/j.rbmo.2018.10.012. View

18.

Koechling W, Plaksin D, Croston G, Jeppesen J, Macklon K, Andersen C . Comparative pharmacology of a new recombinant FSH expressed by a human cell line. Endocr Connect. 2017; 6(5):297-305. PMC: 5510450. DOI: 10.1530/EC-17-0067. View

19.

Clark N, Podolski A, Brooks E, Chizen D, Pierson R, Lehotay D . Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome. Reprod Sci. 2014; 21(8):1034-1043. PMC: 4126218. DOI: 10.1177/1933719114522525. View